FHL’s Unique Approach
We believe that neurodegenerative diseases are complex syndromes with multiple underlying causes such as genetic and environmental factors with symptoms and pathologies for different patients.
We prioritize patients' needs and aims to make discoveries that can transform patients' lives and improve population health with our precision-medicine approach. Our drugs are characterized by the best of two worlds: the patient friendliness of oral/nasal administration and the upregulation of gene activity associated with gene therapies.
Our Approach
Neuronal Protection
-
SMALL MOLECULE, NCE
FHL-101
Program Target
PD
Development Stage
Phase 2
-
SMALL MOLECULE, NCE
FHL-201
Program Target
AD / PD
Development Stage
Pre-Clinical
-
SMALL MOLECULE, REFOCUSED
FHL-301
Program Target
AD / PD
Development Stage
Phase 2
Lysosomal Biogenesis and Autophagy
-
SMALL MOLECULE, NCE
FHL-201
Program Target
AD / PD
Development Stage
Pre-Clinical
-
SMALL MOLECULE, REFOCUSED
FHL-301
Program Target
AD / PD
Development Stage
Phase 2
Attenuating Inflammation in the Brain
-
SMALL MOLECULE, NCE
FHL-101
Program Target
PD
Development Stage
Phase 2
-
SMALL MOLECULE, NCE
FHL-201
Program Target
AD / PD
Development Stage
Pre-Clinical
-
SMALL MOLECULE, REFOCUSED
FHL-301
Program Target
AD / PD
Development Stage
Phase 2
-
PEPTIDE, NCE
FHL-401
Program Target
AD / PD
Development Stage
Pre-Clinical
-
PEPTIDE, NCE
FHL-501
Program Target
AD / PD
Development Stage
Pre-Clinical
-
SMALL MOLECULE, REFOCUSED
FHL-601
Program Target
PD
Development Stage
Pre-Clinical